#ACR25 Abstr#1526 Finally it’s here! Consensus-based guidance on GC #steroid tapering in patients with #SLE. Included considerations before tapering, tapering schedules and monitoring during tapering. Looking forward to the uptake and hearing patients’ views @RheumNow #ACRBest https://t.co/FFl2TFhtTa

REPLENISH - Secukinumab Works in Polymyalgia Rheumatica Novartis announced the results of their REPLENISH trial showing the efficacy of secukinumab (Cosentyx) (SEC) in adults with polymyalgia rheumatica (PMR). https://t.co/CLmCdBXiOf https://t.co/z20nWd2NSM

#0850 Single-cell RNA-seq of RA synovium uncovers a new biomarker & therapeutic target: PHIF Made by Tph cells, drives macrophage activation and mirrors disease severity. Big step forward in understanding RA immunopathogenesis. @RheumNow #ACR25 https://t.co/KtyxU0Lqly

This retrospective study evaluated incidence of MACE & mortality among PsA pts on GLP-1RAs vs non-GLP-1RAs After propensity score matching, pts on GLP-1RAs = ⬇️ risk of developing MACE & ⬇️ mortality vs. non GLP-1RAs Interesting data, More research reqd #ACR25 @RheumNow Abs0849 https://t.co/hiPpQH0K3O

TriNetX database 4000+ pts PsA + GLP-1 RA & 86000+ PsA non GLP-1 ctrls Without much surprise GLP-1 treated pts had lower risk of MACE and death Observational, retrospective study. Now awaiting the prospective evidence. RCT on the way but capturing MACE and death are always https://t.co/GWbAMC1mJK

In the #ACR25 Great AI debate, @RADoctor shows automated ultrasound scanning - one legitimately promising application ready very soon. I’ve written about this work (ARTHUR/DIANA) for @RheumNow last year - check it out: https://t.co/Zq4ywEjspi https://t.co/3RYCVunE3a

#0852 LEVI-04, a novel p75NTR-Fc fusion protein, significantly reduces MRI bone marrow lesions in knee #OA 🦵📉 Phase II RCT (n=518): dose-dependent BML reduction (p<0.001) + correlated improvement in pain & function. Promising structure-modifying OA therapy @RheumNow #ACR25 https://t.co/huA8OaFGSd

@JYazdanyMD in the #ACR25 Great AI Debate details out three key risks of AI in rheumatology: - bias at scale - erosion of skills - data regulatory issues (for what it’s worth, amongst all the potential upside, I think it’s very real. It’s up to us to make it better) @RheumNow https://t.co/FyNes40Z7q

In this ph2 trial of LEVI-04 for knee #osteoarthritis, At wk 20, LEVI-04 ⬇️ bone marrow lesions (BML), greater ⬇️ in BML area even w/ higher KL grades Promising treatment. #ACR25 @RheumNow Abs0852 #ACRBest https://t.co/MrmLPlFiDs

Summary take home points by Dr Highland 1. PAH and PH-ILD are associated with high mortality in patients with SARDs 2. Multimodal and early screening is recommended 3. “It takes a village” work with Pulm and Cardiology colleagues @RheumNow #ACR2025 https://t.co/Xa7TecMOIe